Literature DB >> 25077947

iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes.

Almudena Martinez-Fernandez1, Timothy J Nelson1, Santiago Reyes1, Alexey E Alekseev1, Frank Secreto1, Carmen Perez-Terzic1, Rosanna Beraldi1, Hoon-Ki Sung1, Andras Nagy1, Andre Terzic2.   

Abstract

BACKGROUND: Nuclear reprogramming inculcates pluripotent capacity by which de novo tissue differentiation is enabled. Yet, introduction of ectopic reprogramming factors may desynchronize natural developmental schedules. This study aims to evaluate the effect of imposed transgene load on the cardiogenic competency of induced pluripotent stem (iPS) cells. METHODS AND
RESULTS: Targeted inclusion and exclusion of reprogramming transgenes (c-MYC, KLF4, OCT4, and SOX2) was achieved using a drug-inducible and removable cassette according to the piggyBac transposon/transposase system. Pulsed transgene overexpression, before iPS cell differentiation, hindered cardiogenic outcomes. Delayed in counterparts with maintained integrated transgenes, transgene removal enabled proficient differentiation of iPS cells into functional cardiac tissue. Transgene-free iPS cells generated reproducible beating activity with robust expression of cardiac α-actinin, connexin 43, myosin light chain 2a, α/β-myosin heavy chain, and troponin I. Although operational excitation-contraction coupling was demonstrable in the presence or absence of transgenes, factor-free derivatives exhibited an expedited maturing phenotype with canonical responsiveness to adrenergic stimulation.
CONCLUSIONS: A disproportionate stemness load, caused by integrated transgenes, affects the cardiogenic competency of iPS cells. Offload of transgenes in engineered iPS cells ensures integrity of cardiac developmental programs, underscoring the value of nonintegrative nuclear reprogramming for derivation of competent cardiogenic regenerative biologics.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  induced pluripotent stem cells; nuclear reprogramming; regeneration; regenerative medicine; stem cells

Mesh:

Substances:

Year:  2014        PMID: 25077947      PMCID: PMC4273857          DOI: 10.1161/CIRCGENETICS.113.000298

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  52 in total

1.  Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery.

Authors:  Carmen Perez-Terzic; Randolph S Faustino; Brian J Boorsma; D Kent Arrell; Nicolas J Niederländer; Atta Behfar; Andre Terzic
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-02

Review 2.  Gene regulatory networks in the evolution and development of the heart.

Authors:  Eric N Olson
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

3.  Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.

Authors:  Timothy J Nelson; Almudena Martinez-Fernandez; Satsuki Yamada; Carmen Perez-Terzic; Yasuhiro Ikeda; Andre Terzic
Journal:  Circulation       Date:  2009-07-20       Impact factor: 29.690

4.  Induced pluripotent stem cells--a cautionary note.

Authors:  Christine Mummery
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

5.  Induced pluripotent stem cells: an emerging theranostics platform.

Authors:  T J Nelson; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2011-05       Impact factor: 6.875

6.  c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells.

Authors:  Almudena Martinez-Fernandez; Timothy J Nelson; Yasuhiro Ikeda; Andre Terzic
Journal:  J Cardiovasc Transl Res       Date:  2010-02       Impact factor: 4.132

Review 7.  The use of induced pluripotent stem cells in drug development.

Authors:  H Inoue; S Yamanaka
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

8.  Copy number variation and selection during reprogramming to pluripotency.

Authors:  Samer M Hussein; Nizar N Batada; Sanna Vuoristo; Reagan W Ching; Reija Autio; Elisa Närvä; Siemon Ng; Michel Sourour; Riikka Hämäläinen; Cia Olsson; Karolina Lundin; Milla Mikkola; Ras Trokovic; Michael Peitz; Oliver Brüstle; David P Bazett-Jones; Kari Alitalo; Riitta Lahesmaa; Andras Nagy; Timo Otonkoski
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

9.  Somatic coding mutations in human induced pluripotent stem cells.

Authors:  Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

10.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

View more
  5 in total

Review 1.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

Review 2.  Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.

Authors:  Kiran Musunuru; Farah Sheikh; Rajat M Gupta; Steven R Houser; Kevin O Maher; David J Milan; Andre Terzic; Joseph C Wu
Journal:  Circ Genom Precis Med       Date:  2018-01-12

Review 3.  Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes.

Authors:  Thomas Eschenhagen; Christine Mummery; Bjorn C Knollmann
Journal:  Cardiovasc Res       Date:  2015-01-24       Impact factor: 10.787

4.  An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Stem Cells Int       Date:  2022-09-22       Impact factor: 5.131

Review 5.  Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease.

Authors:  Alexis Bosman; Michael J Edel; Gillian Blue; Rodney J Dilley; Richard P Harvey; David S Winlaw
Journal:  J Clin Med       Date:  2015-04-22       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.